Top image

Carlomagno GroupCollaborations

Teresa Carlomagno

  • Methodology for drug design
    Sanofi Aventis, Frankfurt, Germany

    C. Griesinger, MPI, Göttingen, Germany
    AstraZeneca, UK and Sweden
  • RNP complexes
    R. Pillai, EMBL Grenoble, France 

    B. Reif, FMP, Berlin, Germany
  • Proteasome binders

    M. Kalesse, University of Hannover, Germany 

  • V-ATPase inhibitors
    D. Menche, Heidelberg University, Germany

    M.Huss, H. Wieczorek, University of Osnabrück, Germany
  • Tubulin and proteasome binders
    M. Kalesse, University of Hannover, Germany